TY - JOUR AU - Panika, Ram Kumar AU - Sahu, Rupesh PY - 2019/02/22 Y2 - 2024/03/28 TI - Evaluation of coverage, compliance of mass drug administration and assessment of awareness about lymphatic filariasis in Tikamgarh district of Madhya Pradesh: a cross sectional study JF - International Journal Of Community Medicine And Public Health JA - Int J Community Med Public Health VL - 6 IS - 3 SE - Original Research Articles DO - 10.18203/2394-6040.ijcmph20190618 UR - https://www.ijcmph.com/index.php/ijcmph/article/view/4266 SP - 1235-1240 AB - <p class="abstract"><strong>Background:</strong> Lymphatic filariasis is the second leading cause of disability worldwide accounting for more than 5 million disability adjusted life years annually. It has been a major public health problem in India which leads to irreversible chronic manifestations which are responsible for considerable economic loss and severe physical disability to the affected individuals. Mass drug administration (MDA) means administration of diethylcarbamazine and albendazole tablets to all people (excluding children &lt;2 years, pregnant women, seriously ill persons) in endemic areas once in a year. The objective of the study was to assess coverage, compliance of MDA and awareness about lymphatic filariasis in Tikamgarh district of Madhya Pradesh.</p><p class="abstract"><strong>Methods:</strong> Cross-sectional study was conducted and total 120 households were surveyed in four randomly selected clusters of Tikamgarh district of Madhya Pradesh.</p><p class="abstract"><strong>Results:</strong> Out of total 743 persons 678 (91.25%) persons were eligible for MDA. Coverage rate was 86.57% and compliance rate was 74.27%. The main reason for non-compliance was not having the concerned disease (55.78%) followed by fear of side effect (22.31%). Only 40.83% among the surveyed families were aware about MDA and only 45.83% respondents had heard about lymphatic filariasis.</p><p class="abstract"><strong>Conclusions:</strong> There is coverage and compliance gap and awareness about the lymphatic filariasis and MDA program is limited. Drug compliance need to be improved and awareness need to be raised. MDA program should not be confined to tablet distribution only and due importance should be given to compliance rate.</p> ER -